Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Suvorexant

FDA-approved product (tablet, oral), marketed as Belsomra.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Suvorexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Suvorexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sleep Trial to Prevent Alzheimer's Disease

    NCT04629547 · start 2022-05-25

    Registered record
    Registry ID
    NCT04629547
    Conditions
    Sleep; Alzheimer Disease
    Interventions
    Suvorexant 20 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-05-25
    Completion
    2028-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep; Alzheimer Disease
    InterventionSuvorexant 20 mg; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

    NCT05106153 · start 2021-12-17

    Registered record
    Registry ID
    NCT05106153
    Conditions
    Healthy Non-dependent, Recreational Sedative Users; Abuse Potential
    Interventions
    Suvorexant; Zolpidem; Seltorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-12-17
    Completion
    2023-05-12
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Non-dependent, Recreational Sedative Users; Abuse Potential
    InterventionSuvorexant; Zolpidem; Seltorexant; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Medication Development in Alcoholism: Suvorexant Versus Placebo

    NCT04229095 · start 2021-11-17

    Registered record
    Registry ID
    NCT04229095
    Conditions
    Alcohol Use Disorder (AUD)
    Interventions
    Suvorexant 20 mg; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-11-17
    Completion
    2022-11-08
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder (AUD)
    InterventionSuvorexant 20 mg; Placebo oral tablet
    PhasePhase 2
    Registry statusCompleted

  • Suvorexant to Reduce Symptoms of Nicotine Use

    NCT04234997 · start 2021-08-23

    Registered record
    Registry ID
    NCT04234997
    Conditions
    Smoking Cessation
    Interventions
    Suvorexant 20 mg; Suvorexant 0mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-08-23
    Completion
    2024-08-22
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation
    InterventionSuvorexant 20 mg; Suvorexant 0mg
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

    NCT04706091 · start 2021-08-12

    Registered record
    Registry ID
    NCT04706091
    Conditions
    Restless Legs Syndrome; Insomnia; Sleep Disorder
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-12
    Completion
    2023-10-20
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome; Insomnia; Sleep Disorder
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

    NCT04262193 · start 2021-02-01

    Registered record
    Registry ID
    NCT04262193
    Conditions
    Opioid-use Disorder; Sleep
    Interventions
    Suvorexant; Suvorexant Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-02-01
    Completion
    2024-07-30
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-use Disorder; Sleep
    InterventionSuvorexant; Suvorexant Placebo
    PhasePhase 2
    Registry statusTerminated

  • Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

    NCT04287062 · start 2020-11-20

    Registered record
    Registry ID
    NCT04287062
    Conditions
    Sleep Disturbance; Opioid-use Disorder
    Interventions
    Suvorexant; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-20
    Completion
    2025-08-15
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disturbance; Opioid-use Disorder
    InterventionSuvorexant; Placebos
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

    NCT04571944 · start 2020-10-22

    Registered record
    Registry ID
    NCT04571944
    Conditions
    Delirium
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-10-22
    Completion
    2022-12-23
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    InterventionSuvorexant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Suvorexant and Sleep/Delirium in ICU Patients

    NCT04092894 · start 2020-02-28

    Registered record
    Registry ID
    NCT04092894
    Conditions
    Insomnia; Sleep Fragmentation; Sleep Initiation and Maintenance Disorders; Postoperative Delirium
    Interventions
    Suvorexant 20 mg; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-28
    Completion
    2025-07-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Sleep Fragmentation; Sleep Initiation and Maintenance Disorders; Postoperative Delirium
    InterventionSuvorexant 20 mg; Placebo oral tablet
    PhasePhase 4
    Registry statusCompleted

  • Targeting Orexin to Treat Nicotine Dependence

    NCT03999099 · start 2019-09-26

    Registered record
    Registry ID
    NCT03999099
    Conditions
    Nicotine Dependence
    Interventions
    Suvorexant 20 mg; Suvorexant 10 mg; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-26
    Completion
    2023-07-31
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNicotine Dependence
    InterventionSuvorexant 20 mg; Suvorexant 10 mg; Placebo oral tablet
    PhasePhase 1
    Registry statusCompleted

  • Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence

    NCT03897062 · start 2019-08-26

    Registered record
    Registry ID
    NCT03897062
    Conditions
    Insomnia; Alcohol Use Disorder
    Interventions
    Suvorexant 20 mg; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-08-26
    Completion
    2022-07-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Alcohol Use Disorder
    InterventionSuvorexant 20 mg; placebo
    PhasePhase 2
    Registry statusTerminated

  • Suvorexant and Cocaine

    NCT03937986 · start 2019-07-11

    Registered record
    Registry ID
    NCT03937986
    Conditions
    Cocaine Use Disorder
    Interventions
    Suvorexant; Cocaine; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2019-07-11
    Completion
    2022-04-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorder
    InterventionSuvorexant; Cocaine; Placebo oral capsule
    PhaseEarly phase 1
    Registry statusCompleted

  • Medical Management of Sleep Disturbance During Opioid Tapering

    NCT03789214 · start 2019-07-01

    Registered record
    Registry ID
    NCT03789214
    Conditions
    Opioid Dependence; Opioid Withdrawal; Sleep Disturbance
    Interventions
    Placebo oral capsule; Low Dose Suvorexant; High Dose Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2021-06-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence; Opioid Withdrawal; Sleep Disturbance
    InterventionPlacebo oral capsule; Low Dose Suvorexant; High Dose Suvorexant
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

    NCT04014387 · start 2019-06-02

    Registered record
    Registry ID
    NCT04014387
    Conditions
    Progressive Supranuclear Palsy(PSP); Insomnia
    Interventions
    Suvorexant; Zolpidem; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-06-02
    Completion
    2025-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Supranuclear Palsy(PSP); Insomnia
    InterventionSuvorexant; Zolpidem; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

    NCT03768713 · start 2019-04-18

    Registered record
    Registry ID
    NCT03768713
    Conditions
    Chronic Insomnia
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04-18
    Completion
    2023-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Insomnia
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusUnknown